Darifenacin
Sponsors
Novartis, Warner Chilcott, Cognitive Research Corporation, University of Missouri-Columbia, Center for Clinical Pharmacology Research Bdbeq S.A.
Conditions
BioequivalencyHTLV-1HealthyHealthy VolunteersNeurogenic Detrusor OveractivityNocturiaOveractive BladderOveractive Bladder (OAB)
Phase 1
Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
CompletedNCT00703703
Start: 2008-05-31End: 2008-10-31Updated: 2012-08-02
Single Dose Two-periods Crossover Bioequivalence Study of Darifenacin Tablets in Healthy Volunteers.
NCT01227811
Start: 2010-11-30End: 2011-03-31Target: 24Updated: 2010-10-25
Single Dose Bioequivalence Study of Darifenacin Tablets 7.5 mg in Fed Healthy Volunteers.
NCT01229280
Start: 2010-12-31End: 2011-02-28Target: 24Updated: 2010-10-27
Phase 2
Cognitive Effects of Darifenacin and Oxybutynin Extended Release in Volunteers Aged 60 and Over
CompletedNCT00170768
Start: 2005-02-28End: 2005-05-31Updated: 2008-01-23
A Two-week Open-label Pharmacodynamic and Pharmacokinetic Study of Multiple Doses of a Darifenacin Liquid Oral Suspension in Children (2 - 15 Years) With Neurogenic Detrusor Overactivity
TerminatedNCT00712322
Start: 2008-10-07End: 2013-05-23Updated: 2022-06-09
Phase 3
A Long-Term Safety, Tolerability and Efficacy Study of Darifenacin in Adult Patients With Overactive Bladder
CompletedNCT00170755
Start: 2002-04-30End: 2005-01-31Updated: 2008-01-17
A 12-Week Study to Evaluate the Efficacy of Darifenacin to Increase the Warning Time in Patients With Overactive Bladder.
CompletedNCT00171145
Start: 2004-04-30End: 2004-12-31Updated: 2008-01-23
Efficacy of Darifenacin and Physiotherapy for the Treatment of Overactive Bladder in Women
CompletedNCT02143570
Start: 2014-05-31End: 2016-04-30Updated: 2016-05-02
Phase 4
Using Behavioral Therapy in Combination With Darifenacin for Symptoms of Overactive Bladder
CompletedNCT00127270
Start: 2005-05-31End: 2006-02-28Updated: 2008-01-24
Efficacy, Safety, and Tolerability of Darifenacin in Patients Aged > 65 Years With Overactive Bladder
CompletedNCT00171184
Start: 2005-04-30End: 2006-06-30Updated: 2017-05-18
Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder
CompletedNCT00366002
Start: 2006-06-30End: 2007-09-30Updated: 2008-01-15
Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
CompletedNCT00413790
Start: 2006-11-30End: 2007-09-30Updated: 2008-01-15
Exploratory Study Evaluating the Effects of Darifenacin on Nocturia, Sleep and Daytime Wakefulness
WithdrawnNCT01018225
Start: 2009-11-30End: 2010-07-31Updated: 2016-04-13
Darifenacin x Parasacral Transcutaneous Electric Nerve Stimulation for OAB in Patients Infected With Human T-Lymphotropic Virus 1
CompletedNCT06616675
Start: 2022-03-16End: 2023-12-20Updated: 2024-10-01
Unknown Phase
Preoperative Use of Darifenacin (Enablex) to Alleviate Postoperative Ureteral Stent Pain
TerminatedNCT01189071
Start: 2009-08-31End: 2011-07-31Updated: 2016-11-21
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
CompletedNCT03572231
Start: 2018-07-19End: 2020-03-30Updated: 2020-04-22
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
CompletedNCT03602508
Start: 2018-07-20End: 2019-09-13Updated: 2024-10-16